(PharmaNewsWire.Com, September 23, 2017 ) Find out in the CMO industry's authoritative analysis of manufacturing of NDA approvals. This CMO scorecard was compiled through hundreds of professional hours of research and analysis, and is presented in a 40-page report with over 30 graphs and tables. Only CMO Scorecard enables the CMO industry to benchmark its performance over time, and CMOs to benchmark their performance against the industry.
Our research team crunched the numbers on 2016 drug approvals authorized by FDA's CDER, CBER, Fast Track and Breakthrough drugs, and selected EMA approved drugs. For the first time, we are including information on the location of outsourced dose manufacturing facilities.
This report is required reading for - - CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers. - Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Table of Contents: Executive Summary Introduction NDA Approvals Overview US vs. EU Approval Performance Outsourced Dose Manufacture Special Product Categories Outsourcing by Global Bio/Pharma Companies Outsourced Dose Form Manufacture by Country CMO Performance Outsourced API Approvals What It Means Note on Methodology Appendix Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001761661/sample
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
